Tylenol's crisis manager Lawrence Foster dies at 88

Share this article:

The man behind Johnson & Johnson's legend-making response to the 1982 Tylenol poisoning scare has died. The New York Times reports that Lawrence Foster, a former journalist and head of J&J's PR department, died at the age of 88. Foster had cancer and heart failure.

Under Foster's direction, the company halted all Tylenol advertising and pulled more than 30 million bottles off the shelves. Seven died after consuming capsules that had been tampered with after production and cyanide was added to capsules already on store shelves. According to a University of Florida project about the crisis, Tylenol's hold on the market fell from 37% to 7%.

Foster advised Johnson & Johnson's then-chair James Burke to be the face of the reputation campaign that is now a touchstone of crisis management and led to the brand rising to a 30% market share after the product returned to stores. Foster's strategy was to provide a human element and ownership of the crisis, without polish. Then-chair of McNeil, David Collins, tells the Times Foster's direction was “tell them what we know, and we're not going to tell them what we don't know. We'll tell them we don't know, and we'll get back to them when we do know.”

The company's multi-prong strategy for regaining consumer confidence included tamper-resistant packaging (and replacing capsules with caplets), consumer discounts, and sending sales reps into the field to talk to doctors about the product's integrity.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.